Logo

American Heart Association

  2
  0


Final ID: 4146087

Danish Pragmatic Randomized Trial to Evaluate the Effect of HeartLogic-Guided Management on Heart Failure Outcomes – The DANLOGIC-HF Preliminary Registry Findings

Abstract Body (Do not enter title and authors here): Background: Hospitalizations due to heart failure (HF) are costly and detrimental to patient health. The HeartLogic (HL) algorithm has been found to be predictive of impending HF decompensation.
Purpose: To present characteristics of the Danish nationwide DANLOGIC-HF population and preliminary findings on the performance of the HL algorithm.
Methods: All Danish patients with a HL compatible device implanted after 2017 were identified. Their retrospective HL index values were used to calculate active alert periods. HF status and other diagnoses were based on ICD10 diagnoses codes, and patients with a CRT-D were categorized as having known HF regardless of ICD10 diagnoses. The association between HL alerts and HF hospitalizations were assessed using a Cox proportional hazard model with alert status as a time-dependent covariate and clustered standard errors.
Results: In this population of 1599 adult patients with a CRT-D or ICD, mean age was 59.6 years,75% were male, and 26.9% had ischemic heart disease. While 43% had known HF, only 24% of the population had a CRT-D. Aside from diabetes (7.4% vs 2.7%, p<0.001) and chronic obstructive pulmonary lung disease (3.5% vs 0.5%, p>0.001) being more frequent in patients with HF, the prevalence of cardiovascular comorbidities was similar between patients. Patients with HF had a lower left ventricular ejection fraction (LVEF) (29% vs 44%, p<0.001) and higher NYHA class at implantation compared to patients without HF. Patients with HF also had a higher HF-related hospitalization rate (30 vs 7 per 100 patient-year, p<0.001).
At a mean follow-up time of 2.9 patient-years, HF at baseline and LVEF significantly modified the association between HL alert status and risk of HF hospitalization. The hazard ratio of being hospitalized with HF while in active HeartLogic alert was 7.9 [5.7, 11.1] for the entire population, 5.4 [3.8, 7.6] for patients with known HF and 14.7 [6.0, 36.4] for patients without known HF (p for interaction <0.001). For patients with a LVEF<40%, the hazard ratio for being hospitalized with HF if having an active HL alert was 7.1 [4.9, 10.6] compared with 33.7 [7.3, 157] for patients with a LVEF>40% (p for interaction = 0.026).
Conclusion: Being in active alert was associated with a high risk of being hospitalized with HF, especially among patients without known HF. These findings emphasize the potential utility of HL-guided management in improving HF outcomes, both amongst patients with and without known HF.
  • Witten Davodian, Lise  ( CTCPR - Herlev and Gentofte Hospital , Hellerup , Denmark )
  • Chien, Christopher  ( Knight Cardiovascular Institute , Portland , Oregon , United States )
  • Fudim, Marat  ( Duke University Medical Center , Durham , North Carolina , United States )
  • Hernandez, Adrian  ( Duke University Medical Center , Durham , North Carolina , United States )
  • Kwan, Brian  ( Boston Scientific , Saint Paul , Minnesota , United States )
  • Stolen, Craig  ( Boston Scientific , Saint Paul , Minnesota , United States )
  • Biering-soerensen, Tor  ( CTCPR - Herlev and Gentofte Hospital , Hellerup , Denmark )
  • Dyrby Johansen, Niklas  ( CTCPR - Herlev and Gentofte Hospital , Hellerup , Denmark )
  • Sattler, Stefan Michael  ( Herlev and Gentofte Hospital , Gentofte , Denmark )
  • Wolsk, Emil  ( Herlev and Gentofte Hospital , Gentofte , Denmark )
  • Risum, Niels  ( Rigshospitalet University Hospital , Copenhagen , Denmark )
  • Kober, Lars  ( Rigshospitalet University Hospital , Copenhagen , Denmark )
  • Gustafsson, Finn  ( Rigshospitalet University Hospital , Copenhagen , Denmark )
  • Davodian, Danny  ( CTCPR - Herlev and Gentofte Hospital , Hellerup , Denmark )
  • Solomon, Scott  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Author Disclosures:
    Lise Witten Davodian: DO have relevant financial relationships ; Research Funding (PI or named investigator):Boston Scientific:Active (exists now) | Christopher Chien: DO have relevant financial relationships ; Consultant:Boston Scientific:Active (exists now) ; Consultant:Abbott Laboratories:Past (completed) ; Consultant:Biotronik:Active (exists now) | Marat Fudim: DO NOT have relevant financial relationships | Adrian Hernandez: DO have relevant financial relationships ; Researcher:AstraZeneca:Active (exists now) ; Researcher:Verve:Active (exists now) ; Researcher:Intellia:Active (exists now) ; Researcher:NovoNordisk:Active (exists now) ; Researcher:Merck:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Researcher:Cytokinetics:Active (exists now) ; Researcher:Amgen:Active (exists now) ; Researcher:Boehringer Ingelheim:Active (exists now) ; Researcher:Bayer:Active (exists now) | Brian Kwan: DO have relevant financial relationships ; Employee:Boston Scientific:Active (exists now) ; Individual Stocks/Stock Options:Boston Scientific:Active (exists now) | Craig Stolen: DO have relevant financial relationships ; Employee:Boston Scientific:Active (exists now) ; Individual Stocks/Stock Options:Medtronic (Spouse):Active (exists now) ; Employee:Medtronic (Spouse):Active (exists now) ; Individual Stocks/Stock Options:Boston Scientific:Active (exists now) | Tor Biering-Soerensen: No Answer | Niklas Dyrby Johansen: No Answer | Stefan Michael Sattler: DO NOT have relevant financial relationships | Emil Wolsk: No Answer | Niels Risum: No Answer | Lars Kober: DO have relevant financial relationships ; Speaker:Astra Zeneca:Active (exists now) ; Speaker:Novartis:Active (exists now) ; Speaker:Novo:Active (exists now) ; Speaker:Boehringer:Active (exists now) | Finn Gustafsson: DO have relevant financial relationships ; Advisor:Pfizer:Past (completed) ; Advisor:Alnylam:Active (exists now) ; Advisor:Astra-Zeneca:Active (exists now) | Danny Davodian: No Answer | Scott Solomon: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/BridgeBio, Gossamer, GSK, Ionis, Lilly,NIH/NHLBI, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, US2.AI:Active (exists now) ; Consultant:Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Intellia, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Valo:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Latest and Greatest in the Medical Management of Heart Failure

Monday, 11/18/2024 , 01:30PM - 02:45PM

Abstract Oral Session

More abstracts on this topic:
Candidemia in Patients with Left Ventricular Assist Device-A Case Series

Johnson Adedoyin, Sama Jacob, Eltayeb A.a Abdalla, Rao Roopa, Schenkelberg Laurie, Ilonze Onyedika

A meta-analysis of myocardial recovery and its associated factors in advanced heart failure with left ventricular assist device

Hasabo Elfatih A., Soliman Osama, Isik Burce, Bakr Mohamed, Mahmmoud Fadelallah Eljack Mohammed, Neiroukh Dina, Nosir Mahmoud, Ayhan Cagri, Sultan Sherif, Caliskan Kadir

More abstracts from these authors:
Navigating the Negotiation Process

Mukherjee Monica, Fudim Marat

Defining Severe Heart Failure across the Ejection Fraction Spectrum in DAPA-HF and DELIVER

Inciardi Riccardo, De Boer Rudolf, Hernandez Adrian, Shah Sanjiv, Kober Lars, Ponikowski Piotr, Sabatine Marc, Petersson Magnus, Langkilde Anna Maria, Mcmurray John, Vaduganathan Muthiah, Lu Henri, Solomon Scott, Claggett Brian, Desai Akshay, Jhund Pardeep, Lam Carolyn, Kosiborod Mikhail, Inzucchi Silvio, Martinez Felipe

You have to be authorized to contact abstract author. Please, Login
Not Available